Skip to content

Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)

Fractures

This is a study designed to see if a low dose of Lithium treatment, taken for 2 weeks, can improve fracture healing and improve patients' function and productivity.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 55

Participation Criteria

Inclusion Criteria:

1. Age 18-55 years.
2. ASA (American Society of Anesthesiologists) ≤ 2 class (healthy) prior to injury.
3. Diaphyseal fracture of the humerus, femur or combined tibia/fibula (OTA diaphyseal subclass 2A or B), and clavicle (OTA diaphyseal subclass B1 or B2), with or without nerve injury.
4. Fracture that is primarily closed or open fracture that has complete wound coverage.
5. Randomization ≤14 days from injury or surgery (for surgical patients).
6. Fractures treated surgically or nonsurgically by endochondral/secondary bone healing.
7. For surgical patients, surgery must be within 14 days of injury.

Exclusion Criteria:

1. Currently pregnant or breastfeeding.
2. Any past or current malignancy that, in the opinion of an investigator, is not medically controlled.
3. Metabolic bone disease based on clinical history that, in the opinion of an investigator, is not medically controlled.
4. Autoimmune disease that, in the opinion of an investigator, is not medically controlled.
5. Hypothyroidism based on clinical history that, in the opinion of an investigator, is not medically controlled.
6. Renal impairment based on clinical history.
7. Past allergy or adverse reaction to Lithium.
8. Lactose intolerance.
9. Fractures surgically treated with absolute stability/primary bone healing.
10. Isolated tibia or isolated fibula fracture.
11. Currently taking Lithium or anti-psychotic or anti-seizure medication for the treatment of these conditions or at the discretion of an investigator.
12. Inability to comply with study protocol, in the opinion of the investigator(s).
13. Participation in another interventional clinical trial, at the discretion of the principal investigator.
14. Use of concomitant ultrasound or other bone stimulation device.

Study Location

Hamilton Health Sciences
Hamilton Health Sciences
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Jodi Gallant

[email protected]
Royal Victoria Regional Health Centre
Royal Victoria Regional Health Centre
Barrie, Ontario
Canada

Contact Study Team

Primary Contact

Kelly Cruise

[email protected]
705-728-9090
Unity Health St. Michael's Hospital
Unity Health St. Michael's Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Ashmanie Brijmohan

[email protected]
The Ottawa Hospital Civic Campus
The Ottawa Hospital Civic Campus
Ottawa, Ontario
Canada

Contact Study Team

Backup Contact

Melanie Dodd-Moher

[email protected]
613-737-8899
Primary Contact

Steven Papp, MD

[email protected]
613-737-8899
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Katrine Milner

[email protected]
416-480-4285
Backup Contact

BSc

Study Sponsored By
Sunnybrook Health Sciences Centre
Participants Required
More Information
Study ID: NCT02999022